ABCL-037: One Year Remission with Allogeneic Stem Cell Transplantation After Achieving Complete Response by Polatuzumab Vedotin for the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Abstract

Context: In this abstract, we present the patient who underwent allogeneic stem cell transplantation after complete remission with polatuzumab vedotin therapy. Objective: Patients diagnosed with R/R (NHL) have a poor prognosis. Polatuzumab, an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent named vedotin, has a good safety and tolerability profile in patients with R/R NHL. Polatuzumab helps to achieve complete remission in R/R NHL patients and gives a chance to stem cell transplantation. Design: We determine one R/R NHL patient who achieved complete remission with PoV. The patient had experienced allogeneic stem cell transplantation after PoV treatment. Setting: The patient was diagnosed with R/R NHL conducted in our clinic. Patient: The patient was male, 32-year-old. He was diagnosed with T cell/histiocyte-rich large B cell lymphoma and refractory to R-CHOP, autolog stem cell transplantation, R-ICE and R-DHAP protocols. He had a complete remission after PoV. Interventions: Patient is in remission after allogeneic stem cell transplantation. Main Outcomes Measures: The primary end points were the overall response rate and overall survival (OS). Secondary end points were safety and relapse-free survival (RFS). Results: The patient had well tolerated PoV and had complete remission after 6 cycles of PoV plus rituksimab and bendamustin treatment. The patient is now at +300 days after allogeneic stem cell transplantation. Conclusions: PoV, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has a good activity in combination with rituximab and bendamustine in patients diagnosed with relapsed or refractory non-Hodgkin lymphomas. PoV is well-tolerated with a better safety profile in R/R DLBCL patients and help to achieve a complete remission.